Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Moodys
Boehringer Ingelheim
Mallinckrodt
Colorcon

Last Updated: March 31, 2020

DrugPatentWatch Database Preview

ENBREL Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ENBREL

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Rochester General HospitalPhase 1
RTI InternationalPhase 1
Nova Southeastern UniversityPhase 1

See all ENBREL clinical trials

Recent Litigation for ENBREL

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC.2019-12-31
CELGENE CORPORATION v. HETERO LABS LIMITED2019-07-16
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12

See all ENBREL litigation

PTAB Litigation
PetitionerDate
Dr. Reddy's Laboratories, Inc.2018-08-03
2014-11-06
2013-08-15

See all ENBREL litigation

Pharmacology for ENBREL

Company Disclosures: US Patents for ENBREL

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2012-03-07 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2014-02-25 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2009-09-05 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2009-09-11 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ENBREL

These patents were identified by searching patent claims

Supplementary Protection Certificates for ENBREL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017C/054 Belgium   Start Trial PRODUCT NAME: KEVZARA - SARILUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
CR 2017 00061 Denmark   Start Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196/001-8 20170627
LUC00125 Luxembourg   Start Trial PRODUCT NAME: APREMILAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE:
132017000135500 Italy   Start Trial PRODUCT NAME: SARILUMAB(KEVZARA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1196, 20170627
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Express Scripts
McKesson
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.